These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 22052375)

  • 1. Antiretroviral therapy-associated dyslipidemia in patients from a reference center in Brazil.
    Ceccato MG; Bonolo PF; Souza Neto AI; Araújo FS; Freitas MI
    Braz J Med Biol Res; 2011 Nov; 44(11):1177-83. PubMed ID: 22052375
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increased risk of lipodystrophy when nucleoside analogue reverse transcriptase inhibitors are included with protease inhibitors in the treatment of HIV-1 infection.
    van der Valk M; Gisolf EH; Reiss P; Wit FW; Japour A; Weverling GJ; Danner SA;
    AIDS; 2001 May; 15(7):847-55. PubMed ID: 11399957
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of antiretroviral choice on hypercholesterolaemia events: the role of the nucleoside reverse transcriptase inhibitor backbone.
    Jones R; Sawleshwarkar S; Michailidis C; Jackson A; Mandalia S; Stebbing J; Bower M; Nelson M; Gazzard BG; Moyle GJ
    HIV Med; 2005 Nov; 6(6):396-402. PubMed ID: 16268821
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Body fat changes among antiretroviral-naive patients on PI- and NNRTI-based HAART in the Swiss HIV cohort study.
    Young J; Rickenbach M; Weber R; Furrer H; Bernasconi E; Hirschel B; Tarr PE; Vernazza P; Battegay M; Bucher HC
    Antivir Ther; 2005; 10(1):73-81. PubMed ID: 15751765
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessment of adipokine expression and mitochondrial toxicity in HIV patients with lipoatrophy on stavudine- and zidovudine-containing regimens.
    Jones SP; Qazi N; Morelese J; Lebrecht D; Sutinen J; Yki-Jărvinen H; Back DJ; Pirmohamed M; Gazzard BG; Walker UA; Moyle GJ
    J Acquir Immune Defic Syndr; 2005 Dec; 40(5):565-72. PubMed ID: 16284533
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lipodystrophic syndromes and hyperlipidemia in a cohort of HIV-1-infected patients receiving triple combination antiretroviral therapy with a protease inhibitor.
    Rakotoambinina B; Médioni J; Rabian C; Jubault V; Jais JP; Viard JP
    J Acquir Immune Defic Syndr; 2001 Aug; 27(5):443-9. PubMed ID: 11511820
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Morphological and metabolic components of lipodystrophy in various nevirapine-based highly active antiretroviral therapy (HAART) regimens: a cross-sectional, observational study.
    Guaraldi G; Zona S; Orlando G; Carli F; Stentarelli C; Luzi K; Garlassi E; Menozzi M; Bagni P; Adorni F
    Clin Drug Investig; 2011 Nov; 31(11):759-67. PubMed ID: 21919542
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dyslipidemia in AIDS patients on highly active antiretroviral therapy.
    Nery MW; Martelli CM; Turchi MD
    Braz J Infect Dis; 2011; 15(2):151-5. PubMed ID: 21503402
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lipodystrophy and metabolic changes in HIV-infected children on non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy.
    Aurpibul L; Puthanakit T; Lee B; Mangklabruks A; Sirisanthana T; Sirisanthana V
    Antivir Ther; 2007; 12(8):1247-54. PubMed ID: 18240864
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dyslipidemia in HIV Infected Children Receiving Highly Active Antiretroviral Therapy.
    Mandal A; Mukherjee A; Lakshmy R; Kabra SK; Lodha R
    Indian J Pediatr; 2016 Mar; 83(3):226-31. PubMed ID: 26334860
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lipodystrophy and dyslipidemia in human immunodeficiency virus-infected Thai patients receiving antiretroviral therapy.
    Chuapai Y; Kiertiburanakul S; Malathum K; Sungkanuparph S
    J Med Assoc Thai; 2007 Mar; 90(3):452-8. PubMed ID: 17427520
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Successful simplification of protease inhibitor-based HAART with triple nucleoside regimens in children vertically infected with HIV.
    Palma P; Romiti ML; Cancrini C; Pensieroso S; Montesano C; Santucci MB; Bernardi S; Martino AM; Rossi P; Castelli-Gattinara G
    AIDS; 2007 Nov; 21(18):2465-72. PubMed ID: 18025883
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Initial highly-active antiretroviral therapy with a protease inhibitor versus a non-nucleoside reverse transcriptase inhibitor: discrepancies between direct and indirect meta-analyses.
    Chou R; Fu R; Huffman LH; Korthuis PT
    Lancet; 2006 Oct; 368(9546):1503-15. PubMed ID: 17071284
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A syndrome of lipoatrophy, lactic acidaemia and liver dysfunction associated with HIV nucleoside analogue therapy: contribution to protease inhibitor-related lipodystrophy syndrome.
    Carr A; Miller J; Law M; Cooper DA
    AIDS; 2000 Feb; 14(3):F25-32. PubMed ID: 10716495
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Highly active antiretroviral therapy and dyslipidemia in people living with HIV/AIDS in Fako Division, South West Region of Cameroon.
    Nsagha DS; Weledji EP; Assob NJ; Njunda LA; Tanue EA; Kibu OD; Ayima CW; Ngowe MN
    BMC Cardiovasc Disord; 2015 Aug; 15():95. PubMed ID: 26315756
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Contribution of nucleoside analogue reverse transcriptase inhibitors to subcutaneous fat wasting in patients with HIV infection.
    Mallal SA; John M; Moore CB; James IR; McKinnon EJ
    AIDS; 2000 Jul; 14(10):1309-16. PubMed ID: 10930144
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dyslipidemia and lipodystrophy in HIV-infected Thai children on highly active antiretroviral therapy (HAART).
    Lapphra K; Vanprapar N; Phongsamart W; Chearskul P; Chokephaibulkit K
    J Med Assoc Thai; 2005 Jul; 88(7):956-66. PubMed ID: 16241026
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antiretroviral treatment outcome following genotyping in Thai children who failed dual nucleoside reverse transcriptase inhibitors.
    Bunupuradah T; Suntarattiwong P; Li A; Sirivichayakul S; Pancharoen C; Boonrak P; Puthanakit T; Kerr SJ; Ruxrungtham K; Chotpitayasunondh T; Hirschel B; Ananworanich J;
    Int J Infect Dis; 2010 Apr; 14(4):e311-6. PubMed ID: 19699673
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Current treatment strategies, complications and considerations for the use of HIV antiretroviral therapy during pregnancy.
    Senise JF; Castelo A; Martínez M
    AIDS Rev; 2011; 13(4):198-213. PubMed ID: 21975356
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metabolic complications associated with antiretroviral therapy.
    Jain RG; Furfine ES; Pedneault L; White AJ; Lenhard JM
    Antiviral Res; 2001 Sep; 51(3):151-77. PubMed ID: 11448728
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.